Navigation Links
Study reveals details of alternative splicing circuitry that promotes cancer's Warburg effect
Date:11/2/2011

Cold Spring Harbor, N.Y. Cancer cells maintain their life-style of extremely rapid growth and proliferation thanks to an enzyme called PK-M2 (pyruvate kinase M2) that alters the cells' ability to metabolize glucose a phenomenon known as the Warburg effect.

Professor Adrian Krainer, Ph.D., and his team at Cold Spring Harbor Laboratory (CSHL), who seek to reverse this effect and force cancer cells to regain the metabolism of normal cells, have discovered details of molecular events that cause cancer cells to produce PK-M2 instead of its harmless counterpart, an isoform called PK-M1. Their study, performed in collaboration with Professor Lewis Cantley, Ph.D., and his colleagues at Harvard Medical School and The Koch Institute, in Cambridge, Mass, appears on November 1 in the Journal of Molecular Cell Biology.

Both protein isoformsPK-M2 and PK-M1, the latter of which is found only in normal cellsare both encoded by the same gene, PK-M, in a mutually exclusive fashion via a process called alternative splicing. After the gene is transcribed to produce RNA, unneeded bits called introns are first spliced out. How the remaining bits, called exons, are stitched back together by the cell's splicing machinery decides which protein version is produced. In the case of the RNA transcript for PK-M RNA, the choice is between two exons: exon 9, found in PK-M1; and exon 10, whose inclusion results in PK-M2 production.

"In this study, our goal was to determine what exactly the splicing machinery looks for when it's trying to decide which exon to include and which exon to exclude," specifies Krainer. Following a series of experiments in which the team manipulated the two exons within a precursor form of the RNA PK-M by duplicating them, swapping their positions, etc., the scientists discovered that the signals for mutually exclusive splicing reside within the two exons themselves.

The exon 10-inclusion signal is a potent splicing "enhancer" a sequence of nucleotides or "bases" that differs from its counterpart in exon 9 by a mere two nucleotides. These two so-called "wobble bases" are responsible for recruiting a splicing protein called SRSF3, the team has found. "Our discovery that SRFS3 plays a role in promoting the Warburg effect is consistent with other studies that recently identified this protein as having oncogenic properties and found it to be produced at high levels in ovarian and cervical cancer cells," says Krainer.

SRSF3 itself might not make for a good therapeutic target, as it oversees splicing in numerous other genes unrelated to cancer. But Krainer's team is focusing on finding ways to redirect splicing to force cancer cells to preferentially include exon 9 and thereby produce PK-M1 instead of PK-M2. The team has previously been successful in correcting a splicing defect that causes the neuromuscular disease, spinal muscular atrophy, using "antisense" technologywhich involves synthetic nucleotide sequencesto redirect splicing to force the inclusion of a single exon.

"The task at hand is more challenging because it involves mutually exclusive splicing in which one exon has to be included while the inclusion of the other exon has to be prevented," explains Krainer.


'/>"/>

Contact: Hema Bashyam
bashyam@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Exenatide (Byetta) has rapid, powerful anti-inflammatory effect, UB study shows
2. Cancer Risk Doubles After Organ Transplant, Study Finds
3. Yoga Gets Women With Back Pain Moving: Study
4. Study finds overweight teens want to lose weight, going about it the wrong way
5. Many radiologists disagree on management of incidental findings, study finds
6. Handheld Metal Detectors Dont Seem to Affect Pacemakers: Study
7. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
8. The freshman 15 is just a myth, nationwide study reveals
9. First-of-its-kind study creates new tool for targeted cancer drug development
10. Study finds community counseling reduced the prevalence of TB on a budget
11. Practice Doesnt Always Make Perfect, Study Suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use ... nebulizer had a more child-friendly design, then children would be more likely to look ... to avoid the need to deliver medication via a nebulizer mask. The design will ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... NY (PRWEB) , ... December 08, 2016 , ... ... is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods ... in JMIR Medical Informatics . , Results of the comparative usability study ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LONDON , Dec. 8, 2016 KEY ... for the largest share of the market in 2016 ... This dominance can be attributed to a large number ... region. (US hold the largest share in the patient ... several benefits such as reducing loss of blood during ...
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)...  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e ... doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, ... , , ...
Breaking Medicine Technology: